Fineline Cube

Follow:
14855 Articles
Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention
CompanyDrug

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken
Company

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Sanofi's Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps
CompanyDrug

Sanofi’s Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps

Bayer's Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01
CompanyDrug

Bayer’s Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Boehringer Ingelheim and Sino Biopharmaceutical Forge Strategic Multi‑Project ADC and TCE Option Deal – $358 Million Upfront, Up to $7 Billion in Milestones Across Six Preclinical Cancer Programs
CompanyDeals

Boehringer Ingelheim and Sino Biopharmaceutical Forge Strategic Multi‑Project ADC and TCE Option Deal – $358 Million Upfront, Up to $7 Billion in Milestones Across Six Preclinical Cancer Programs

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody
CompanyDeals

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody

Pfizer Raises Full‑Year 2026 Guidance as Q3 Revenue Holds Flat at $16.6 Billion – Launched and Acquired Products Surge 32%, Cecile Guegan Named CFO
Company

Pfizer Raises Full‑Year 2026 Guidance as Q3 Revenue Holds Flat at $16.6 Billion – Launched and Acquired Products Surge 32%, Cecile Guegan Named CFO

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia
CompanyDeals

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

GenFleet's Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors
CompanyDrug

GenFleet’s Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte
CompanyDrug

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China
CompanyDrug

CSPC Pharmaceutical Initiates Phase II Trial of SYH2072 – Self‑Developed Aldosterone Synthase Inhibitor Targeting Uncontrolled and Refractory Hypertension in China

Zuellig Pharma Acquires Licensed Pharmaceutical Entity and Facility in Hangzhou, China – Strategic Move Strengthens Clinical Trial Sourcing Capabilities
CompanyDeals

Zuellig Pharma Acquires Licensed Pharmaceutical Entity and Facility in Hangzhou, China – Strategic Move Strengthens Clinical Trial Sourcing Capabilities